Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

REGAIN Study Group

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)976-986
Number of pages11
JournalThe Lancet Neurology
Volume16
Issue number12
DOIs
StatePublished - Dec 1 2017

Keywords

  • Adult
  • Aged
  • Antibodies, Monoclonal, Humanized/administration & dosage
  • Autoantibodies/blood
  • Double-Blind Method
  • Drug Resistance
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myasthenia Gravis/blood
  • Outcome Assessment, Health Care
  • Receptors, Cholinergic/immunology
  • Severity of Illness Index

Cite this